Viraflu 200 mg is a novel antiviral agent specifically active against influenza viruses. After oral administration, it is metabolized intracellularly into its active form, Viraflu ribosyl triphosphate (Viraflu RTP). This active metabolite selectively inhibits the RNA-dependent RNA polymerase of the influenza virus, thereby blocking viral RNA synthesis and preventing viral replication.

Unlike existing influenza antivirals, Viraflu 200 mg has a distinct mechanism of action and demonstrates in vitro activity against a wide range of influenza viruses, including human influenza A, B, and C, as well as avian and swine influenza strains. This broad antiviral activity makes it particularly valuable in the management of emerging and resistant influenza infections.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Viraflu 200 mg is indicated for:

• Treatment of novel or re-emerging pandemic influenza virus infections

• Cases where other influenza antiviral drugs are ineffective or not sufficiently effective

Use of Viraflu 200 mg should be based on physician judgment and current clinical guidelines.

Dosage and Administration

• Day 1: 1600 mg orally twice daily

• Day 2 to Day 5: 600 mg orally twice daily

The total duration of treatment is 5 days, or as directed by a registered physician. The tablets should be taken orally and can be administered with or without food.

Drug Interactions

Comprehensive human interaction data are limited. In animal studies, Viraflu 200 mg has shown:

• Decreased red blood cell production

• Elevations in liver enzymes such as AST, ALT, ALP, and total bilirubin

• Increased vacuolization in hepatocytes

Caution is advised when co-administered with other drugs affecting hepatic or renal function.

Contraindications

Viraflu 200 mg is contraindicated in:

• Pregnant women

• Women who may possibly be pregnant

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

The most commonly reported adverse effects include:

• Diarrhea

• Increased blood uric acid levels

Other potential adverse effects may emerge as further clinical data become available.

Pregnancy and Lactation

Viraflu 200 mg may cause delayed embryonic development or fetal death during early pregnancy. It should not be used during pregnancy. Adequate contraception is required for women of childbearing potential during treatment and for at least 7 days after completion of therapy. Data on use during lactation are not sufficient.

Precautions and Warnings

• Pregnancy must be ruled out prior to initiation of therapy

• Effective contraception is mandatory during and shortly after treatment

• Use with caution in patients with hepatic or renal impairment

• Should only be used under the supervision of a registered physician

Overdose Effects

Animal studies indicate potential toxicity, including:

• Reduced red blood cell production

• Elevated liver function parameters

• Hepatocellular vacuolization

There is limited information regarding overdose effects in humans.

Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of reach of children.

Use in Special Populations

Viraflu 200 mg is currently approved as an experimental drug. Further studies are required to establish its long-term safety, efficacy, and appropriate use, particularly in pediatric patients.

Drug Class

Anti-viral drugs

Mode of Action

Viraflu 200 mg inhibits influenza virus replication by selectively targeting viral RNA polymerase through its active metabolite, thereby preventing viral RNA synthesis and spread.